Peregrine Capital Management LLC Has $4.91 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Peregrine Capital Management LLC decreased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 32.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 135,678 shares of the specialty pharmaceutical company's stock after selling 63,974 shares during the quarter. Peregrine Capital Management LLC owned about 0.25% of Supernus Pharmaceuticals worth $4,906,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Supernus Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock worth $61,000 after buying an additional 352 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth $72,000. Venturi Wealth Management LLC purchased a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth about $92,000. KBC Group NV increased its position in shares of Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company's stock worth $97,000 after acquiring an additional 929 shares during the last quarter. Finally, Kennebec Savings Bank acquired a new position in Supernus Pharmaceuticals in the third quarter worth about $103,000.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,103.38. This represents a 6.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Trading Down 4.1 %

NASDAQ:SUPN traded down $1.43 during mid-day trading on Friday, hitting $33.17. The company's stock had a trading volume of 371,256 shares, compared to its average volume of 423,048. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of 30.92 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The stock has a fifty day moving average of $37.55 and a 200-day moving average of $35.27.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald downgraded Supernus Pharmaceuticals from an "overweight" rating to a "neutral" rating and reduced their price objective for the stock from $57.00 to $36.00 in a research report on Wednesday.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.